Recommended Guidelines For Pharmaceutical Distribution System

Quality Assurance of Pharmaceuticals
Fortieth Report
A Compendium of Guidelines and Related Materials. Good manufacturing practices and inspection
The Realities of Safety and Security : Hearing Before the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Ninth Congress, First Session, on Examining the Realities of Safety and Security Regarding Drug Importation, February 16, 2005
Sick Crime
Emergence of an Open Information Infrastructure in China's Pharmaceutical Distribution Industry
Pharmaceutical Supply Chain Security
Rules and Guidance for Pharmaceutical Distributors 2015
Hearings Before a Subcommittee of the Committee on Appropriations, United States Senate, One Hundred Eighth Congress, Second Session, on H.R. 4766/S. 2803, an Act Making Appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Programs for the Fiscal Year Ending September 30, 2005, and for Other Purposes : Department of Agriculture, Department of Health and Human Services: Food and Drug Administration, Nondepartmental Witnesses
An Analysis of Medicines, Regulations and Pharmaceutical Systems in the Global South
Counterfeit Drugs in the United States : Hearing Before the Subcommittee on Criminal Justice, Drug Policy, and Human Resources of the Committee on Government Reform, House of Representatives, One Hundred Ninth Congress, First Session, November 1, 2005
Rules and Guidance for Pharmaceutical Manufacturers and Distributors
Counterfeit Drugs: Coming to a Pharmacy Near You (2009)
Rules and Guidance for Pharmaceutical Manufacturers and Distributors 2007
Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use
Rules and Guidance for Pharmaceutical Distributors 2007
Managing Drug Supply
Understanding Drugs Markets
WHO Expert Committee on Specifications for Pharmaceutical Preparations
fifty-fifth report
Code of Practice and Minimum Standards for Pharmaceutical Wholesale and Distribution
Pain Management and the Opioid Epidemic
Rules and Guidance for Pharmaceutical Manufacturers and Distributors 2002
Guidelines for Selecting Pharmaceutical Manufacturers and Distributors
Fifty-Third Report
Countering the Problem of Falsified and Substandard Drugs
Hearing Before the Subcommittee on Criminal Justice, Drug Policy, and Human Resources of the Committee on Government Reform, House of Representatives, One Hundred Ninth Congress, Second Session, July 11, 2006
Rules and Guidance for Pharmaceutical Manufacturers and Distributors (The Orange Guide) 2013
Innovating in a Learning Community
WHO guideline on country pharmaceutical pricing policies
The Selection, Procurement, Distribution, and Use of Pharmaceuticals
The International Pharmacopoeia
Forty-ninthReport
Rules and Guidance for Pharmaceutical Manufacturers and Distributors (Orange Guide) 2022
Agriculture, Rural Development, and Related Agencies Appropriations for Fiscal Year 2005
WHO Expert Committee on Specifications for Pharmaceutical Preparations
Drug Quality and Security Act
Regulatory Affairs in the Pharmaceutical Industry
Rules and Guidance for Pharmaceutical Manufacturers and Distributors 2015

SHANIA WEBB

Quality Assurance of Pharmaceuticals Springer Science & Business Media
The Expert Committee on Specifications for Pharmaceutical Preparations works towards clear, independent and practical standards and guidelines for the quality assurance of medicines and provision of global regulatory tools. Standards are developed by the Expert Committee through worldwide consultation and an international consensus-building process. The following new guidance texts were adopted and recommended for use: Guidelines and guidance texts adopted by the Expert Committee on Specifications for Pharmaceutical Preparations; Points to consider when including Health Based Exposure Limits (HBELs) in cleaning validation; Good manufacturing practices: water for pharmaceutical use; Guideline on data integrity; WHO/United Nations Population Fund recommendations for condom storage and shipping temperatures; WHO/United Nations Population Fund guidance on testing of male latex condoms; WHO/United Nations Population Fund guidance on conducting post-market surveillance of condoms; WHO “Biowaiver List”: proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms; WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce; Good reliance practices in the regulation of medical products: high-level principles and considerations; and Good regulatory practices in the regulations of medical products. All of the above are included in this report and recommended for implementation.
Fortieth Report World Health Organization
This report presents the recommendations of an international group of experts convened by the World Health Organization to consider matters concerning the quality assurance of pharmaceuticals and specifications for drug substances and dosage forms. Annexes include: a list of available international chemical reference substances and international infrared spectra; supplementary guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms; updated supplementary guidelines on good manufacturing practices for the manufacture of herbal medicines; supplementary guidelines on good manufacturing practices for validation; good distribution practices for pharmaceutical products; a model quality assurance system for procurement agencies (recommendations for quality assurance systems focusing on prequalification of products and manufacturers, purchasing, storage and distribution of pharmaceutical products); multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability; a proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms; and additional guidancefor organizations performing in vivo bioequivalence studies.
A Compendium of Guidelines and Related Materials. Good manufacturing practices and inspection World Health Organization
This edition of Managing Drug Supply provides a complete overview, as well as step-by-step approaches, on how to manage pharmaceutical systems effectively.
The Realities of Safety and Security : Hearing Before the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Ninth Congress, First Session, on Examining the Realities of Safety and Security Regarding Drug Importation, February 16, 2005 Routledge
The Expert Committee on Specifications for Pharmaceutical Preparations works towards clear, independent and practical standards and guidelines for the quality assurance of medicines. Standards are developed by the Committee through worldwide consultation and an international consensus-building process. The following new guidelines were adopted and recommended for use: Procedure for development of the WHO medicines quality assurance guidelines; Guidelines on Good Manufacturing Practices (GMP) for heating, ventilation and air-conditioning systems (HVAC) illustrative part; Guidance on GMP for Validation, including the general main text, analytical procedure validation, validation of computerized systems and qualification; in the area of interchangeability of multisource medicines: the Protocol to conduct equilibrium solubility experiments for the purpose of biopharmaceutics classification systembased classification of active pharmaceutical ingredients for biowaiver; Guidelines on Import Procedures for pharmaceutical products; and the Good Practice Guidance document on implementing the collaborative procedures. All of the above are included in this report and recommended for implementation.
Sick Crime Bernan Assoc
Throughout history, the development and application of technology has been crucial to progress in healthcare provision. The shape that healthcare processes take will impact not only the quality of the resulting service but also the way in which suppliers of healthcare products will need to operate to make the most of their opportunities. In this cutting edge guide to strategic supply chain management, Rob Whewell shows how to develop a strategy to protect your pharmaceutical business from key threats whether legal or illegal. Parallel trading and counterfeit drugs, the requirements of organizations such as the FDA demanding more rigorous controls and traceability, new technologies and new ways of working with wholesalers or alternative distributors, all offer a new flexibility in manufacturing and the ability to respond to immediate opportunities or crises in any given market. The authoritatively written Supply Chain in the Pharmaceutical Industry provides you with the means to develop a strategic approach to supply chain that allows you to minimize risk and ensure flexibility and improved long-term profitability.
Emergence of an Open Information Infrastructure in China's Pharmaceutical Distribution Industry World Health Organization
This publication, known as the "Orange Guide", has been an essential reference for those involved in the manufacture or distribution of medicines in Europe. The Orange Guide collates in one convenient and authoritative source European and UK guidance documents and information on legislation relating to the manufacture and distribution of medicines for human use. In the production and distribution of medicines for human use, compliance with Good Manufacturing Practice and Good Distribution Practice is a necessity. Changes to this particular edition include: detailed changes to the EU guide to good manufacturing practice; detailed revisions to the EU Directive on medicinal products for human use; the new Directive on the Principles and Guidelines on Good Manufacturing Practice of Medicinal Products for Human Use. The document is compiled by the Inspection and Standards Division of the Medicines and Healthcare products Regulatory Agency.
Pharmaceutical Supply Chain Security WHO
Compiled by the Medicines and Healthcare products Regulatory Agency (MHRA), this new publication provides guidance for distributors of medicines for human use in Europe. Essential information to ensure the safe distribution of medicines and the safety of the public is provided in this new guide.
Rules and Guidance for Pharmaceutical Distributors 2015 National Academies Press

Drawing on anthropology, historical sociology and social-epidemiology, this multidisciplinary book investigates how pharmaceuticals are produced, distributed, prescribed, (and) consumed, and regulated in order to construct a comprehensive understanding of the issues that drive (medicine) pharmaceutical markets in the Global South today. Based on primary research conducted in Benin and Ghana, and additional data collected in Cambodia and the Ivory Coast, this volume uses artemisinin-based combination therapies (ACTs) against malaria as a central case study. It highlights the influence of the countries colonial and post-colonial history on their models for state regulation, production, and distribution, explores the determining role transnational actors as well as industries from the North but also and increasingly from the South play in influencing local pharmaceutical markets and looks at the behaviour of health care professionals and individuals. Stepping back, the authors then unpick the pharmaceuticalization process and the multiple regulations at stake by looking at the workings of, and linkages between, (biomedical health) pharmaceutical systems, (representatives of companies) industries, actors in private distribution, and consumer practices. Providing a thorough comparative analysis of the advantages and disadvantages of different pharmaceutical systems, it is an important contribution to the literature on pharmaceutalization and the governance of medication. It is of interest to students, researchers and policy-makers interested in medical anthropology, the sociology of health and illness, global health, healthcare management and pharmacy. The Open Access version of this book, available at http://www.taylorfrancis.com/books/9780429329517, has been made available under a Creative Commons Attribution-Non Commercial-No Derivatives 4.0 license.

Hearings Before a Subcommittee of the Committee on Appropriations, United States Senate, One Hundred Eighth Congress, Second Session, on H.R. 4766/S. 2803, an Act Making Appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Programs for the Fiscal Year Ending September 30, 2005, and for Other Purposes : Department of Agriculture, Department of Health and Human Services: Food and Drug Administration, Nondepartmental Witnesses World Health Organization

How do firms jointly develop open information infrastructures? To answer this question, this book draws on the results of a longitudinal research project covering the development of the pharmaceutical distribution industry in China from 2004 to 2012, focusing on the emergence and subsequent evolution of industry-wide information infrastructures. How do firms delimit areas of proprietary innovation in open innovation projects? How do firms coordinate, initiate, negotiate and implement the development of innovative infrastructures? How do processes and practices within firms enable and constrain such collective efforts? - This book provides answers to these questions and draws conclusions regarding the challenges and new capabilities that firms will need in a world in which participation in the building of open information infrastructures becomes a necessary task for commercial organizations.

An Analysis of Medicines, Regulations and Pharmaceutical Systems in the Global South Rules and Guidance for Pharmaceutical Distributors (Green Guide) 2022Rules and Guidance for Pharmaceutical Distributors (Green Guide) 2017A single source of guidance to, and legislation for, the distribution of medicines in Europe and UK.Rules and Guidance for Pharmaceutical Manufacturers and Distributors (Orange Guide) 2017Commonly known as the Orange Guide, this book remains an essential reference for all manufacturers and distributors of medicines in Europe. It provides a single authoritative source of European and UK guidance, information and legislation relating to the manufacture and distribution of human medicines.Countering the Problem of Falsified and Substandard Drugs

The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today. The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines.

Counterfeit Drugs in the United States : Hearing Before the Subcommittee on Criminal Justice, Drug Policy, and Human Resources of the Committee on Government Reform, House of Representatives, One Hundred Ninth Congress, First Session, November 1, 2005 National Academies Press

Commonly known as the Orange Guide, this book remains an essential reference for all manufacturers and distributors of medicines in Europe. It provides a single authoritative source of European and UK guidance, information and legislation relating to the manufacture and distribution of human medicines.

Rules and Guidance for Pharmaceutical Manufacturers and Distributors Stationery Office Books (TSO)

A collection of recommended procedures for analysis and specifications for the determination of pharmaceutical substances, excipients and dosage forms intended to serve as source material for reference by any WHO member state.

Counterfeit Drugs: Coming to a Pharmacy Near You (2009) World Health Organization

Commonly known as the "Orange Guide," this publication brings together the main pharmaceutical regulations and directives which manufacturers and wholesalers are expected to follow when making and distributing medicinal products in the European Union and European Economic Area.

Rules and Guidance for Pharmaceutical Manufacturers and Distributors 2007 CRC Press

Over the years, the World Health Organization's Expert Committee on Specifications for Pharmaceutical Preparations, originally created to prepare The International Pharmacopoeia, has made numerous recommendations relevant to quality assurance and control for national regulatory and control systems and the implementation of international standards, but for the most part they have only been available in the annexes to various technical reports. In this second of two volumes, those annexes providing guidelines related to good manufacturing practices and to inspection of manufacturers and drug distribution channels have been gathered and revised. Annotation : 2004 Book News, Inc., Portland, OR (booknews.com).

Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use World Health Organization

This new edition of The Green Guide provides a single source of guidance to, and legislation for, the distribution of medicines in Europe and UK. The Green Guide takes all the elements of the new Rules and Guidance for Pharmaceutical Manufacturers and Distributors 2014 (the Orange Guide) that are relevant to distributors, and reproduces them. Since the last edition in 2007, there have been significant changes and additions to the detailed European Community guidelines on Good Distribution Practice (GDP). The Community code relating to medicinal products for human use has also been substantially amended and the new edition brings together information about these important changes

Rules and Guidance for Pharmaceutical Distributors 2007 Academic Press

A comprehensive exploration of the massive changes in the biopharmaceutical supply chain that have occurred during the past 10 years, and predicted future trends, Biopharmaceutical Supply Chains: Distribution, Regulatory, Systems and Structural Changes Ahead documents the specific impacts of these changes for key players in the supply chain. Based

Managing Drug Supply CRC Press

This title is an essential reference work for all those involved in the distribution of medicines in Europe. It reproduces relevant parts of Rules and Guidance for Pharmaceutical Manufacturers and Distributors (commonly known as the Orange Guide) specific to wholesale supply and distribution of medicines for human use. It is compiled by the UK drug regulatory body, the MHRA, and contains official EU guidance on good distribution practice and wholesale distribution along with relevant information on EU and UK legislation. It brings together the main pharmaceutical regulations, directives and guidance which manufacturers and wholesalers are expected to follow when distributing medicinal products within Europe. This 2015 edition of Rules and Guidance for Pharmaceutical Distributors (the Green Guide) has been updated to incorporate the revised EU Guidelines on Good Distribution Practice.

Understanding Drugs Markets World Health Organization

This report presents the recommendations of an international group of experts convened by the World Health Organization to consider matters concerning the quality assurance of pharmaceuticals and specifications for drug substances and dosage forms. The report is complemented by a number of annexes. These include: a list of available international chemical reference substances and international infrared spectra; supplementary guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms; updated supplementary guidelines on good manufacturing practices for the manufacture of herbal medicines; supplementary guidelines on good manufacturing practices for validation; good distribution practices for pharmaceutical products; a model quality assurance system for procurement agencies (recommendations for quality assurance systems focusing on prequalification of products and manufacturers, purchasing, storage and distribution of pharmaceutical products); multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability; a proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms; and additional guidance for organizations performing in vivo bioequivalence studies. ...This is an excellent book with a misleading title... a good reference work for anyone seeking to understand the concept of validation and looking for general guidance on validation for both Active Pharmaceutical Ingredients (API) and finished pharmaceutical products. Annex 5 on Good distribution practices (GDP) for pharmaceutical products is an excellent Annex that splits the task of GDP into 20, small, easy to digest sections that guide the reader through the process of understanding the complexity of controlling distribution of pharmaceutical products. It contains a comprehensive glossary of terms used in GDP... a useful reference book for anyone involved in Quality Assurance, Manufacturing of marketed products, Clinical Manufacturing and Development. - Industrial Pharmacy

WHO Expert Committee on Specifications for Pharmaceutical Preparations Gower Publishing, Ltd.

The World Health Organization (WHO) Expert Committee on Specifications for Pharmaceutical Preparations advises the Director-General of WHO in the area of medicines quality assurance. It provides independent expert recommendations and guidance to ensure that medicines meet standards of quality, safety and efficacy in all WHO Member States. Its advice is developed through a broad consensus-building process and covers all areas of quality assurance of medicines, from their development to their distribution to patients. In the area of quality control, the Expert Committee reviewed new and revised specifications and general texts for inclusion in The International Pharmacopoeia, and received the annual report of the European Directorate for the Quality of Medicines & HealthCare (EDQM), the custodian centre for International Chemical Reference Substances (ICRS). The Committee adopted a number of monographs, general texts and ICRS. It noted the report on Phase 6 of the External Quality Assurance Assessment Scheme (EQAAS) and on new approaches to ensure sustainability of this scheme through user fees. The Committee further acknowledged the progress of good pharmacopoeial practices (GPhP), and adopted the document on GPhP which was prepared by the consecutive international meetings of world pharmacopoeias. In the various quality assurance-related areas the Expert Committee was presented with a number of new and revised guidelines related to good manufacturing practices (GMP), distribution and trade of pharmaceuticals and regulatory practice. It adopted 10 guidelines as listed below as well as 22 new specifications and general texts for inclusion in The International Pharmacopoeia. The Committee took note of ongoing work to promote collaboration and information exchange through the good regulatory practice project and welcomed the development of a comprehensive set of guidelines for all national regulatory authorities through this project.

fifty-fifth report Am Cncl on Science, Health

Regulatory Affairs in the Pharmaceutical Industry is a comprehensive reference that compiles all the information available pertaining to regulatory procedures currently followed by the pharmaceutical industry. Designed to impart advanced knowledge and skills required to learn the various concepts of regulatory affairs, the content covers new drugs, generic drugs and their development, regulatory filings in different countries, different phases of clinical trials, and the submission of regulatory documents like IND (Investigational New Drug), NDA (New Drug Application) and ANDA (Abbreviated New Drug Application). Chapters cover documentation in the pharmaceutical industry, generic drug development, code of Federal Regulation (CFR), the ANDA regulatory approval process, the process and documentation for US registration of foreign drugs, the regulation of combination products and medical devices, the CTD and ECTD formats, and much more. Updated reference on drug approval processes in key global markets Provides comprehensive coverage of concepts and regulatory affairs Presents a concise compilation of the regulatory requirements of different countries Introduces the fundamentals of manufacturing controls and their regulatory importance